2
Palobiofarma achieves “first patient first visit” in two key Phase II studies
Palobiofarma has recruited the first patient in the two key multicenter Phase II clinical studies. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients and the efficacy of PBF-680 is mild to moderate asthmatics.